2025 United Kingdom Antibodies Contract Manufacturing Revenue Opportunities Report
Description
The 2025 United Kingdom Antibodies Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibodies contract manufacturing in the United Kingdom include Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., and Fujifilm Diosynth Biotechnologies. Lonza Group has a strong global footprint and extensive biologics manufacturing capabilities, making it a key player in antibody production. Catalent extends its services with significant European facility expansions focused on advanced therapies, including antibodies. Charles River Laboratories provides comprehensive development and manufacturing services, supporting antibody-based therapeutic programs. Fujifilm Diosynth Biotechnologies is prominent in biologics manufacturing with facilities delivering high-quality antibody products for various biopharmaceutical companies.
These firms benefit from the UK's robust biotech ecosystem and leadership in advanced therapies such as cell and gene therapies. Growth in the antibody contract manufacturing market is driven by rising demand for therapeutic antibodies targeting cancers and chronic diseases. Advancement in biomanufacturing technologies and increasing outsourcing trends among biopharmaceutical companies further boost market participation. The UK market itself is expected to grow substantially, supported by these major CDMOs investing in capacity and innovative manufacturing processes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibodies contract manufacturing in the United Kingdom include Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., and Fujifilm Diosynth Biotechnologies. Lonza Group has a strong global footprint and extensive biologics manufacturing capabilities, making it a key player in antibody production. Catalent extends its services with significant European facility expansions focused on advanced therapies, including antibodies. Charles River Laboratories provides comprehensive development and manufacturing services, supporting antibody-based therapeutic programs. Fujifilm Diosynth Biotechnologies is prominent in biologics manufacturing with facilities delivering high-quality antibody products for various biopharmaceutical companies.
These firms benefit from the UK's robust biotech ecosystem and leadership in advanced therapies such as cell and gene therapies. Growth in the antibody contract manufacturing market is driven by rising demand for therapeutic antibodies targeting cancers and chronic diseases. Advancement in biomanufacturing technologies and increasing outsourcing trends among biopharmaceutical companies further boost market participation. The UK market itself is expected to grow substantially, supported by these major CDMOs investing in capacity and innovative manufacturing processes.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
